The Bone Cancer Research Trust and Children’s Cancer and Leukaemia Group (CCLG) are pleased to announce an exciting collaboration to fund research focused on Ewing sarcoma and osteosarcoma.

Over the past several decades, advancements in the treatment of Ewing sarcoma and osteosarcoma have remained limited. Both involve intensive and toxic chemotherapy regimens, with patients facing gruelling immediate, long-term and late effects of treatment, alongside the risk of relapse and recurrence.

Both charities are committed to improving outcomes for patients and believe the best way to do this is to fund high impact, collaborative research.

Dr Zoe Davison, Head of Research, Support & Information at the Bone Cancer Research Trust, said:

Collaboration is key to making progress through research. It is vital that we join forces and maximise funding to push forward the development of kinder and more effective treatments and ways to personalise treatments. We are thrilled to be working with CCLG to expedite our common goal of improving outcomes for Ewing sarcoma and osteosarcoma patients, ensuring more patients survive and thrive.

Ashley Gamble, CEO at CCLG, shared:

We’re delighted to partner with The Bone Cancer Research Trust to fund high-quality, impactful research that will help change the future for young bone cancer patients. Together, we are stronger. By working together, we can bring closer the day where all young people with osteosarcoma and Ewing sarcoma not only survive their cancer, but do so free from any long-term effects of their treatment.

This funding call marks the beginning of a close working relationship between the two charities across all pillars of work, ensuring a joined up and collegiate approach.

To find out more and how to apply, please visit the link below:

Click here